Efficacy and safety of infliximab in patients with autoimmune hepatitis
Cumali Efe(Medizinische Hochschule Hannover), Fatima Higuera‐de la Tijera(Hospital General de México), Tuğçe Eşkazan(Istanbul University-Cerrahpaşa), Maciej K. Janik(Medical University of Warsaw), Aldo J. Montaño‐Loza(University of Alberta), Alexandra Heurgué(Hôpital Robert-Debré), Θεόδωρος Ανδρουτσάκος(National and Kapodistrian University of Athens), Dilara Turan Gökçe(Ankara Bilkent City Hospital), Christine Bernsmeier(University of Basel), Benedetta Terziroli Beretta‐Piccoli(Ente Ospedaliero Cantonale), Ellina Lytvyak(University of Alberta), Sumita Verma(Brighton and Sussex Medical School), İlkay Ergenç(King's College - North Carolina), Ersin Batıbay(Harran University), Çiğdem Arıkan(Medizinische Hochschule Hannover), Murat Törüner(Ankara University), Pinelopi Arvaniti(University Hospital of Larissa), Joost P.H. Drenth(Amsterdam Neuroscience), Özlem Gül Utku(Lokman Hekim Üniversitesi), Guilherme Macedo(Hospital de São João), İbrahim Hatemı(Istanbul University-Cerrahpaşa), Mustafa Cengiz(Gülhane Askerî Tıp Akademisi), Staffan Wåhlin(Karolinska University Hospital), Kalliopi Zachou(University Hospital of Larissa), Albert Friedrich Stättermayer(Medical University of Vienna), Sezgin Barutçu(Gaziantep University), Piotr Milkiewicz(Medical University of Warsaw), Osman Yüksekyayla(Harran University), Michael A. Heneghan(King's College Hospital NHS Foundation Trust), Einar Björnsson(Reykjavík University), Meral Akdoğan(Türkiye Yüksek İhtisas Hastanesi), Tuğrul Pürnak(Hacettepe University), Rodrigo Liberal(King's College - North Carolina)
Cited by 25
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)
|United European Gastroenterology Journal|2017|698